Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Protagonist Therapeutics Inc PTGX

Healthcare Biotechnology
Protagonist Therapeutics, Inc. is a biopharmaceutical company. The Company uses its peptide-based chemical entities rusfertide and JNJ-2113 in different stages of development, all derived from its proprietary discovery technology platform. The Company’s clinical programs fall into two categories of diseases: hematology and blood disorders, and inflammatory and immunomodulatory diseases. Its... see more

Recent & Breaking News (NDAQ:PTGX)

Protagonist Therapeutics to Participate in the JMP Securities Hematology and Oncology Summit

PR Newswire December 1, 2022

Protagonist Therapeutics Reports Granting of Inducement Award

PR Newswire November 16, 2022

Protagonist Reports Third Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire November 8, 2022

Protagonist Therapeutics Announces Poster Presentations at the American Society of Hematology 2022 Annual Meeting

PR Newswire November 3, 2022

Protagonist Announces Appointment of Arturo Molina, M.D., M.S., F.A.C.P. as Chief Medical Officer

PR Newswire November 2, 2022

Protagonist Therapeutics Reports Granting of Inducement Award

PR Newswire September 20, 2022

Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire August 4, 2022

Protagonist Therapeutics Reports Granting of Inducement Award

PR Newswire July 19, 2022

Protagonist Therapeutics to Participate at the Jefferies Healthcare Conference

PR Newswire June 1, 2022

Protagonist Therapeutics to Present Updated Phase 2 Rusfertide Clinical Results in Polycythemia Vera (PV) at ASCO 2022

PR Newswire May 26, 2022

ROSEN, A TOP RANKED FIRM, Encourages Protagonist Therapeutics, Inc. Investors With Losses to Inquire About Securities Class Action Investigation - PTGX

Newsfile May 17, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protagonist Therapeutics, Inc. - PTGX

PR Newswire May 11, 2022

Protagonist Reports First Quarter 2022 Financial Results and Provides Corporate Update

PR Newswire May 4, 2022

Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile April 29, 2022

Ongoing Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile April 28, 2022

Ongoing Investigation Alert: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile April 27, 2022

Investigation Reminder: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile April 26, 2022

Protagonist Therapeutics Announces Topline Data from Phase 2 IDEAL Study of PN-943 in Ulcerative Colitis

PR Newswire April 25, 2022

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protagonist Therapeutics, Inc. - PTGX

PR Newswire April 25, 2022

Ongoing Investigation Notice: The Schall Law Firm Encourages Investors in Protagonist Therapeutics, Inc. with Losses of $100,000 to Contact the Firm

Newsfile April 25, 2022